ING Groep NV Lowers Holdings in Pfizer Inc. $PFE

ING Groep NV trimmed its stake in Pfizer Inc. (NYSE:PFE) by 8.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 772,114 shares of the biopharmaceutical company’s stock after selling 72,193 shares during the quarter. ING Groep NV’s holdings in Pfizer were worth $19,673,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Krilogy Financial LLC grew its position in Pfizer by 30.1% during the 3rd quarter. Krilogy Financial LLC now owns 80,919 shares of the biopharmaceutical company’s stock valued at $1,991,000 after purchasing an additional 18,699 shares during the last quarter. Madison Asset Management LLC raised its holdings in Pfizer by 20.2% in the third quarter. Madison Asset Management LLC now owns 242,132 shares of the biopharmaceutical company’s stock worth $6,170,000 after buying an additional 40,646 shares during the last quarter. Westbourne Investments Inc. lifted its stake in shares of Pfizer by 1.1% in the third quarter. Westbourne Investments Inc. now owns 82,475 shares of the biopharmaceutical company’s stock worth $2,033,000 after buying an additional 880 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in shares of Pfizer by 4.8% during the third quarter. Advisors Asset Management Inc. now owns 868,327 shares of the biopharmaceutical company’s stock valued at $22,125,000 after buying an additional 39,989 shares during the last quarter. Finally, Signet Investment Advisory Group Inc. increased its position in shares of Pfizer by 8.5% during the third quarter. Signet Investment Advisory Group Inc. now owns 146,879 shares of the biopharmaceutical company’s stock valued at $3,742,000 after acquiring an additional 11,567 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.5%

PFE opened at $27.74 on Thursday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a market capitalization of $157.70 billion, a PE ratio of 20.39 and a beta of 0.47. The firm’s 50 day simple moving average is $25.74 and its two-hundred day simple moving average is $25.15.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the firm earned $0.63 EPS. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.2%. Pfizer’s payout ratio is currently 126.47%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat and upbeat outlook: Pfizer reported Q4 EPS and revenue above expectations and reiterated a positive forward outlook, which is supporting the rally as investors price in steadier earnings. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Unusual options flow: Elevated call-option activity suggests some traders are positioning for further upside after the results, amplifying short‑term bullish momentum. Pfizer Reports Strong Earnings Outlook – Unusual Call Options Activity Shows Investors are Bullish
• Positive Sentiment: Shareholder returns: Management returned $9.8B to shareholders in 2025 (buybacks/dividends), which supports valuation and income-focused investor demand. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders
• Positive Sentiment: Regulatory progress: The FDA granted priority review for HYMPAVZI (marstacimab) sBLA, a pipeline milestone that could add upside if approved. Pfizer Inc. (PFE) announces FDA’s grant of priority review for HYMPAVZI® (marstacimab) sBLA
• Neutral Sentiment: Analyst / press commentary: Several outlets (Seeking Alpha, The Motley Fool, Zacks) publish bullish post‑earnings takes and “look again” pieces that may attract retail interest—but these are opinion pieces rather than new company actions. Pfizer: A Great Opportunity Post Earnings
• Neutral Sentiment: One‑time SEC collection: Pfizer will receive $29M related to an SEC matter tied to a 2013 case—positive to cash flow but immaterial to fundamentals. Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
• Negative Sentiment: Patent cliff and pipeline questions: Analysts and commentary warn of a 2026–2030 patent cliff as COVID-era sales wane; questions remain whether new and acquired drugs will offset lost revenue, pressuring longer‑term growth expectations. Can Pfizer’s New & Acquired Drugs Offset Its Looming Patent Cliff?
• Negative Sentiment: Valuation / “value trap” concerns: Critical pieces highlight execution risk and that the stock’s depressed valuation may reflect real growth challenges—these narratives can cap multiple expansion. Is Pfizer Stock Now A Value Trap?

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Zacks Research downgraded Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Bank of America lowered their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.